{"hq_id":"hq-p-spe-000209","name":"Titanium Orthopedic Implant Corrosion and Metallosis (Ti-6Al-4V Alloy, Fretting Corrosion, Particle-Induced Osteolysis, Metal Ion Release)","category":{"primary":"specialty_hazard","secondary":"orthopedic_implant","tags":["titanium","orthopedic implant","Ti-6Al-4V","metallosis","fretting corrosion","osteolysis","metal ion","hip replacement","knee replacement","implant failure"]},"product_tier":"SPE","overall_risk_level":"moderate","description":"Titanium alloy (Ti-6Al-4V) orthopedic implants — hip arthroplasty stems, knee tibial baseplates, spinal fusion hardware, and fracture fixation plates — are considered the gold standard for biocompatibility, but generate metallic wear debris through fretting corrosion at modular taper junctions, micromotion at bone-implant interfaces, and third-body wear from cement or bone fragments. This mechanically generated titanium, aluminum, and vanadium particulate triggers macrophage-mediated inflammatory cascades (particle-induced osteolysis) that progressively destroy the surrounding bone, leading to implant loosening and revision surgery in 5-15% of patients over 15-20 years. Metallosis — the pathological accumulation of metallic debris in periprosthetic tissue — produces characteristic gray-black tissue staining, pseudotumor formation, elevated serum titanium levels (normal <1 ng/mL; metallosis >5 ng/mL), and local tissue necrosis. Vanadium and aluminum ions released from Ti-6Al-4V are more biologically active than titanium itself: vanadium is cytotoxic to osteoblasts at micromolar concentrations, and aluminum has been implicated in periprosthetic bone mineral density loss.","synthesis":{"derived_risk_level":"insufficient_data","synthesis_confidence":0,"synthesis_method":"none","context_source":null,"compounds_resolved":1,"compounds_total":1,"synthesis_date":"2026-05-09","synthesis_version":"1.2.0","methodology_note":"exposure_modifier and adjusted_magnitude are computed from ALETHEIA-calibrated heuristics (route × duration × frequency multipliers, clamped to [0.5, 1.4]). Multipliers are directionally informed by EPA Exposure Factors Handbook (2011) and CalEPA OEHHA but are not regulatory consensus. See /api/methodology for full disclosure."},"hazard_summary":{"sensitive_populations":"younger active implant recipients (higher wear rates), patients with metal hypersensitivity, patients with renal impairment (reduced metal ion clearance), revision arthroplasty patients (larger modular junctions)","overall_risk":"moderate","primary_concerns":["Particle-induced osteolysis causes progressive bone destruction and implant loosening in 5-15% of patients","Metallosis produces pseudotumors, tissue necrosis, and gray-black tissue staining requiring revision surgery","Vanadium ions cytotoxic to bone-forming osteoblasts at micromolar concentrations","No non-invasive monitoring standard — metallosis often diagnosed late when symptomatic"],"exposure_routes":"Systemic (continuous — metal ion release from implant surface corrosion and wear debris phagocytosis into lymphatic and circulatory systems over implant lifetime)."},"exposure":{"routes":["systemic"],"contact_types":["implant_wear_debris","systemic_ion_release"],"users":["patient_orthopedic","adult","elderly"],"duration":"chronic","frequency":"continuous_lifetime","scenarios":["Hip replacement patient: fretting corrosion at head-neck taper junction generates Ti/Al/V particulate over 10-20 year implant life","Spinal fusion patient: micromotion between pedicle screw and rod releases metal ions into adjacent tissues","Knee replacement patient: tibial baseplate micromotion against polyethylene insert creates third-body titanium wear debris","Fracture plate patient: plate-bone micromotion during healing generates local metallosis requiring hardware removal"],"notes":"Ti-6Al-4V: most widely used orthopedic alloy. Corrosion mechanisms: fretting corrosion (micro-motion at modular junctions, 10-100 um amplitude), crevice corrosion (stagnant fluid in gaps), galvanic corrosion (dissimilar metals). Particle-induced osteolysis: titanium particles 0.1-10 um phagocytosed by macrophages → IL-1, IL-6, TNF-alpha → RANKL upregulation → osteoclast activation → bone resorption → implant loosening. Serum monitoring: titanium normal <1 ng/mL; concern >5 ng/mL; metallosis typically >10 ng/mL. Vanadium toxicity: cytotoxic to osteoblasts at 10-50 uM; inhibits ATPases. Aluminum: competes with calcium at hydroxyapatite binding sites. Revision rate: 5-15% at 15-20 years for total hip arthroplasty (NJR data)."},"consumer_guidance":{"usage_warning":"Patients with titanium orthopedic implants should report unexplained pain, swelling, or joint instability to their orthopedic surgeon, as these may indicate metallosis or particle-induced osteolysis. Request serum metal ion monitoring (titanium, cobalt, chromium) at regular follow-up appointments, especially if symptoms develop. Inform all healthcare providers about implant composition before MRI or other procedures. Joint replacement registries track long-term implant performance — inquire whether your implant model has above-average revision rates.","safer_alternatives":["Highly cross-linked polyethylene bearings (reduce wear debris generation at articulating surfaces)","Ceramic-on-ceramic bearing couples for young active patients (lowest wear rates)","Titanium-niobium alloys (vanadium-free) under development for reduced cytotoxicity","Coated implant surfaces (hydroxyapatite, titanium plasma spray) to improve osseointegration and reduce micromotion"]},"regulatory":{"applicable_regulations":[{"jurisdiction":"USA","regulation":"FDA Premarket Approval and Postmarket Surveillance for Orthopedic Implants","citation":"21 CFR 888 (Orthopedic Devices); FDA Guidance on Metal-on-Metal Hip Implants (2013, updated 2019)","requirements":"Orthopedic implants require 510(k) clearance or PMA depending on classification. FDA mandates postmarket surveillance through the Medical Device Reporting (MDR) system and has issued specific guidance on metal ion monitoring for metal-on-metal hip implants. National Joint Replacement Registries (AJRR in US, NJR in UK) track revision rates by implant model. FDA can issue safety communications and recalls based on postmarket data.","compliance_status":null,"effective_date":null,"enforcing_agency":"FDA Center for Devices and Radiological Health","penalties":null,"source_ref":null}],"certifications":[],"labeling":{"required_disclosures":[],"prop65_warning":{"required":null,"chemicals":[],"endpoint":null,"notes":null},"ghs_labeling":{"required":null,"signal_word":null,"pictograms":[],"hazard_statements":[],"notes":null},"hidden_ingredients":{"trade_secret_protected":null,"categories_hidden":[],"estimated_count":null,"known_concerns":null,"notes":null},"notes":null},"recalls":[],"regulatory_gap":null,"notes":null},"lifecycle":{"recyclable":false,"disposal_guidance":"Explanted titanium implants should be decontaminated per facility protocol and may be recycled through medical metal recycling programs. Tissue specimens with metallosis should be submitted for pathological analysis.","hazardous_waste":false,"expected_lifespan":"15-25 year intended service life; lifetime follow-up recommended for all joint replacement patients"},"formulation":{"form":"varies","key_ingredients":[],"certifications":[]},"materials":{"common":[],"concerning":[],"preferred":[]},"compound_composition":[{"hq_id":"hq-c-ino-000121","compound_name":null,"role":"implant_material","typical_concentration":"Ti-6Al-4V alloy (90% Ti, 6% Al, 4% V); wear debris 0.1-10 um particles; serum Ti normal <1 ng/mL, metallosis >5 ng/mL"}],"identifiers":{"common_names":["titanium orthopedic implant corrosion and metallosis (ti-6al-4v alloy, fretting corrosion, particle-induced osteolysis, metal ion release)"],"aliases":[],"manufacturer":null,"brands":[]},"brand_examples":[],"brand_examples_disclaimer":null,"sources":[{"type":"expert_curation","name":"ALETHEIA Safety Database","date":"2026-03-26"}],"meta":{"schema_version":"4.0.0","last_updated":"2026-03-26","timestamp":"2026-05-14T01:30:56.136Z"}}